204 related articles for article (PubMed ID: 33742986)
1. Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'.
Sobottka B; Lorch A; Silina K; van den Broek M; Moch H
Curr Opin Urol; 2021 May; 31(3):228-235. PubMed ID: 33742986
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
4. Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.
Maruschke M; Reuter D; Koczan D; Hakenberg OW; Thiesen HJ
BJU Int; 2011 Jul; 108(2 Pt 2):E29-35. PubMed ID: 21435154
[TBL] [Abstract][Full Text] [Related]
5. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value.
Zeng Q; Zhang W; Li X; Lai J; Li Z
Life Sci; 2020 Feb; 243():117273. PubMed ID: 31926244
[TBL] [Abstract][Full Text] [Related]
6. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
7. Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study.
Sanchez A; Furberg H; Kuo F; Vuong L; Ged Y; Patil S; Ostrovnaya I; Petruzella S; Reising A; Patel P; Mano R; Coleman J; Russo P; Liu CH; Dannenberg AJ; Chan TA; Motzer R; Voss MH; Hakimi AA
Lancet Oncol; 2020 Feb; 21(2):283-293. PubMed ID: 31870811
[TBL] [Abstract][Full Text] [Related]
8. The tumour microenvironment and metabolism in renal cell carcinoma targeted or immune therapy.
Lai Y; Tang F; Huang Y; He C; Chen C; Zhao J; Wu W; He Z
J Cell Physiol; 2021 Mar; 236(3):1616-1627. PubMed ID: 32783202
[TBL] [Abstract][Full Text] [Related]
9. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
[TBL] [Abstract][Full Text] [Related]
10. A pan-kidney cancer study identifies subtype specific perturbations on pathways with potential drivers in renal cell carcinoma.
Zhan X; Liu Y; Yu CY; Wang TF; Zhang J; Ni D; Huang K
BMC Med Genomics; 2020 Dec; 13(Suppl 11):190. PubMed ID: 33371886
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and prognostic value of FBXO11 expression in patients with clear cell renal cell carcinoma.
Fan B; Wang W; Zhang X; Sun M; Wang X; Chen Z; Liu W; Wang Q; Yu N; Li X
BMC Cancer; 2019 Jun; 19(1):534. PubMed ID: 31159774
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Clinicopathologic Analyses of Acquired Cystic Disease-associated Renal Cell Carcinoma With Focus on Adverse Prognostic Factors and Metastatic Lesions.
Kojima F; Gandhi JS; Matsuzaki I; Iba A; Collier S; Yoshikawa T; Kinoshita Y; Warigaya K; Fujimoto M; Kuroda N; Morii E; Hara I; Murata SI; Amin MB
Am J Surg Pathol; 2020 Aug; 44(8):1031-1039. PubMed ID: 32271189
[TBL] [Abstract][Full Text] [Related]
13. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
14. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy Based on Tumor Microenvironment in Renal Cell Carcinoma].
Han SC; Yin HQ; Xu T
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2022 Apr; 44(2):305-312. PubMed ID: 35538767
[TBL] [Abstract][Full Text] [Related]
16. European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Ljungberg B; Albiges L; Abu-Ghanem Y; Bensalah K; Dabestani S; Fernández-Pello S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Kuusk T; Lam TB; Marconi L; Merseburger AS; Powles T; Staehler M; Tahbaz R; Volpe A; Bex A
Eur Urol; 2019 May; 75(5):799-810. PubMed ID: 30803729
[TBL] [Abstract][Full Text] [Related]
17. The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.
Xu F; Guan Y; Xue L; Huang S; Gao K; Yang Z; Chong T
BMC Cancer; 2020 Dec; 20(1):1207. PubMed ID: 33287763
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the management of advanced and metastatic renal cell carcinoma: joint consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.
Poon DMC; Chan CK; Chan K; Chu WH; Kwong PWK; Lam W; Law KS; Lee EKC; Liu PL; Sze HCK; Wong JHM; Chan ESY
Hong Kong Med J; 2022 Dec; 28(6):475-481. PubMed ID: 35815480
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of extensive necrosis in renal cell carcinoma.
Collins J; Epstein JI
Hum Pathol; 2017 Aug; 66():108-114. PubMed ID: 28669641
[TBL] [Abstract][Full Text] [Related]
20. Importance of Multiparametric Evaluation of Immune-Related T-Cell Markers in Renal-Cell Carcinoma.
Kawashima A; Uemura M; Nonomura N
Clin Genitourin Cancer; 2019 Dec; 17(6):e1147-e1152. PubMed ID: 31473121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
